NASDAQ: ZSTKZerostack Corp Stock
$11.48-0.32 (-2.71%)
Updated Jan 30, 2026
ZSTK Price
$11.48
Fair Value Price
N/A
Market Cap
$8.51M
52 Week Low
$5.86
52 Week High
$47.00
P/E
-0.35x
P/B
0.13x
P/S
0.26x
PEG
N/A
Dividend Yield
N/A
Revenue
$49.66M
Earnings
-$15.96M
Gross Margin
17.5%
Operating Margin
-31.54%
Profit Margin
-32.1%
Debt to Equity
0.14
Operating Cash Flow
-$7M
Beta
1.64
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ZSTK Overview
Flora Growth Corp. offers medicinal cannabis and medicinal cannabis derivative products to pharmacies, medical clinics, and cosmetic companies in the U.S. and internationally. Flora Growth sells its products under the JustCBD, Vessel, Mind Naturals, Mambe, Stardog, Tonino Lamborghini, and Kalaya brands. Flora Growth was incorporated in 2019 and is headquartered in Toronto, Ontario, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ZSTK's potential to beat the market
- ZSTK doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
ZSTK
RankedUnranked of 57
RankedUnranked of 57
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $4.89 | A | |
| $35.38 | A | |
| $40.15 | A |
Be the first to know about important ZSTK news, forecast changes, insider trades & much more!
ZSTK News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ZSTK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ZSTK is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ZSTK is good value based on its book value relative to its share price (0.13x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.68x)
P/B vs Industry Valuation
ZSTK is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ZSTK due diligence checks available for Premium users.
Valuation
ZSTK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.35x
Industry
-89.14x
Market
43.06x
ZSTK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.13x
Industry
1.68x
ZSTK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ZSTK's financial health
Profit margin
Revenue
$9.7M
Net Income
-$6.7M
Profit Margin
-68.3%
ZSTK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ZSTK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$74.0M
Liabilities
$9.1M
Debt to equity
0.14
ZSTK's short-term assets ($18.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZSTK's short-term assets ($18.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZSTK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$100.0k
Investing
$1.3M
Financing
$10.6M
ZSTK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ZSTK vs Pharmaceutical Stocks
Zerostack Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.